Clinical Trial Detail

NCT ID NCT02564263
Title Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

gastroesophageal junction adenocarcinoma

esophagus squamous cell carcinoma

esophagus adenocarcinoma

Therapies

Pembrolizumab

Docetaxel + Irinotecan + Paclitaxel

Age Groups: adult

No variant requirements are available.